TL1A reduces proliferation of activated B-cells.

<p>(<b>A</b>) Representative flow cytometry histograms of CFSE-labeled B cells stimulated (empty curve) or not (grey curve) with 2 µg/ml (n = 8) or 20 µg/ml (n = 3) anti-IgM and 20 U/ml IL-2 for 96 h, in the presence or absence of 100 ng/ml TL1A. Bold numbers indicate percentage of proliferating cells. Analyses are gated on lymphocytes (based on forward and side scatter), and living (7AAD-negative) B cells (CD19-positive). (<b>B</b>) Proliferating B cells were stimulated with 2 µg/ml (n = 8) or 20 µg/ml (n = 3) anti-IgM and 20 U/ml IL-2 for 96 h, in the presence or absence of 100 ng/ml TL1A. Three parameters were calculated (division index, % divided and number of divisions) and represented as distinct histograms. Data are represented as mean±SEM. Comparison between treatments was performed by the two-sample Wilcoxon signed rank sum test. (<b>C</b>) Proliferation of B cells stimulated with 2 µg/ml anti-IgM, 20 U/ml IL-2 for 96 h, in the presence of different doses of TL1A (n = 3). Three parameters were calculated (division index, % divided and number of divisions) and represented as separated histograms. Data are represented as mean±SEM. * = <i>p</i><0.05. (<b>D</b>) Time-course experiment (n = 2) of CFSE-labeled purified B cells stimulated with 2 µg/ml anti-IgM, 20 U/ml IL-2; 2 µg/ml anti-IgM, 20 U/ml IL-2, 100 ng/ml TL1A; 100 ng/ml TL1A; or medium. Three parameters were calculated (division index, % divided and number of divisions) and represented as separated graphs.